## Tsuneyo Mimori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7188888/publications.pdf

Version: 2024-02-01

155 papers 12,435 citations

57631 44 h-index 26548 107 g-index

160 all docs

160 docs citations

times ranked

160

12876 citing authors

#	Article	IF	CITATIONS
1	The International Consensus on ANA Patterns (ICAP) in 2021â€"The 6th Workshop and Current Perspectives. journal of applied laboratory medicine, The, 2022, 7, 322-330.	0.6	31
2	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology, 2022, 61, 4273-4285.	0.9	3
3	Severe joint deformity and patient global assessment of disease are associated with discrepancies between sonographic and clinical remission: A cross-sectional study of rheumatoid arthritis patients. Modern Rheumatology, 2021, 31, 334-342.	0.9	8
4	Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab. Modern Rheumatology, 2021, 31, 678-683.	0.9	23
5	Aicardi–GoutiÔres syndrome-like encephalitis in mutant mice with constitutively active MDA5. International Immunology, 2021, 33, 225-240.	1.8	8
6	Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis. Modern Rheumatology, 2021, 31, 235-240.	0.9	14
7	A case of pulmonary arterial hypertension complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis and systemic sclerosis. Immunological Medicine, 2021, 44, 263-269.	1.4	1
8	Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell, 2021, 184, 3006-3021.e17.	13.5	147
9	Antiâ€dsDNA antibodies recognize DNA presented on HLA class II molecules of systemic lupus erythematosus risk alleles. Arthritis and Rheumatology, 2021, , .	2.9	8
10	Clinical characteristics of four myositis-specific autoantibodies with regulatory-approved testing in Japan: A Japanese multi-centre adult myositis patients' cohort. Journal of Dermatological Science, 2021, 103, 53-56.	1.0	1
11	Dispensable roles of Gsdmd and Ripk3 in sustaining IL- $\hat{1}^2$ production and chronic inflammation in Th17-mediated autoimmune arthritis. Scientific Reports, 2021, 11, 18679.	1.6	4
12	How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative. Immunologic Research, 2021, 69, 594-608.	1.3	34
13	ECG Changes Through Immunosuppressive Therapy Indicate Cardiac Abnormality in Anti-MDA5 Antibody-Positive Clinically Amyopathic Dermatomyositis. Frontiers in Immunology, 2021, 12, 765140.	2.2	4
14	Activated neutrophil carbamylates albumin <i>via</i> the release of myeloperoxidase and reactive oxygen species regardless of NETosis. Modern Rheumatology, 2020, 30, 345-349.	0.9	15
15	Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis. Modern Rheumatology, 2020, 30, 450-457.	0.9	3
16	Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD. Modern Rheumatology, 2020, 30, 551-557.	0.9	5
17	Prediction of recurrence and remission using superb microvascular imaging in rheumatoid arthritis. Journal of Medical Ultrasonics (2001), 2020, 47, 131-138.	0.6	6
18	Feasibility of patient-oriented ultrasound joint selection: Cross-sectional observational study on rheumatoid arthritis. Modern Rheumatology, 2020, 30, 975-981.	0.9	3

#	Article	IF	CITATIONS
19	The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study. Rheumatology International, 2020, 40, 217-225.	1.5	3
20	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. Modern Rheumatology, 2020, 30, 424-433.	0.9	1
21	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Annals of the Rheumatic Diseases, 2020, 79, 387-392.	0.5	17
22	Thigh muscle MRI findings in myopathy associated with antiâ€mitochondrial antibody. Muscle and Nerve, 2020, 61, 81-87.	1.0	13
23	Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency. Arthritis Research and Therapy, 2020, 22, 248.	1.6	2
24	Association of anti-NR2 and U1RNP antibodies with neurotoxic inflammatory mediators in cerebrospinal fluid from patients with neuropsychiatric systemic lupus erythematosus. Lupus, 2020, 29, 1673-1682.	0.8	2
25	Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. PLoS ONE, 2020, 15, e0228852.	1.1	7
26	Predictive factors for structural remission using abatacept: Results from the ABROAD study. Modern Rheumatology, 2019, 29, 406-412.	0.9	7
27	Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Modern Rheumatology, 2019, 29, 589-595.	0.9	96
28	Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naÃ⁻ve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. Modern Rheumatology, 2019, 29, 572-580.	0.9	7
29	PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Annals of the Rheumatic Diseases, 2019, 78, 509-518.	0.5	36
30	lgG4-related disease – A new disease entity developed in the twenty-first century. Modern Rheumatology, 2019, 29, 213-213.	0.9	1
31	Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody–positive Polymyositis/dermatomyositis–associated Interstitial Lung Disease: A Propensity Score–matched Analysis. Journal of Rheumatology, 2019, 46, 509-517.	1.0	18
32	Evaluation of risk factors for atherosclerosis using carotid ultrasonography in Japanese patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2019, 22, 1312-1318.	0.9	3
33	Strain-Specific Manifestation of Lupus-like Systemic Autoimmunity Caused by <i>Zap70</i> Mutation. Journal of Immunology, 2019, 202, 3161-3172.	0.4	15
34	Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease. Rheumatology, 2019, 58, 1465-1473.	0.9	12
35	Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients. Seminars in Arthritis and Rheumatism, 2019, 49, 283-287.	1.6	28
36	Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2019, 49, 204-210.	1.6	7

#	Article	IF	CITATIONS
37	Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders. Internal Medicine, 2019, 58, 5-14.	0.3	5
38	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Modern Rheumatology, 2019, 29, 1-19.	0.9	28
39	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Journal of Dermatology, 2019, 46, e1-e18.	0.6	13
40	Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. International Journal of Rheumatic Diseases, 2019, 22, 1084-1093.	0.9	37
41	Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Modern Rheumatology, 2019, 29, 814-820.	0.9	32
42	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Neurology and Clinical Neuroscience, 2019, 7, 3-21.	0.2	6
43	Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study. Modern Rheumatology, 2019, 29, 314-323.	0.9	34
44	Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease. Modern Rheumatology, 2018, 28, 724-729.	0.9	7
45	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Annals of the Rheumatic Diseases, 2018, 77, 602-611.	0.5	51
46	A concomitant case of pathologically proven IgG4-related disease and ANCA-associated vasculitis: case report. Modern Rheumatology Case Reports, 2018, 2, 84-91.	0.3	2
47	<i>HLA-DRB1</i> Analysis Identified a Genetically Unique Subset within Rheumatoid Arthritis and Distinct Genetic Background of Rheumatoid Factor Levels from Anticyclic Citrullinated Peptide Antibodies. Journal of Rheumatology, 2018, 45, 470-480.	1.0	6
48	Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Modern Rheumatology, 2018, 28, 838-844.	0.9	24
49	Suppressor of TCR signaling-2 (STS-2) suppresses arthritis development in mice. Modern Rheumatology, 2018, 28, 626-636.	0.9	5
50	Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis. European Spine Journal, 2018, 27, 406-415.	1.0	10
51	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Modern Rheumatology, 2018, 28, 642-648.	0.9	16
52	Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission. Medicine (United States), 2018, 97, e11024.	0.4	12
53	Publishing <i>Immunological Medicine</i> -changing from <i>Japanese Journal of Clinical Immunology</i> . Immunological Medicine, 2018, 41, 1-1.	1.4	0
54	TAFRO syndrome complicated with occlusion of multiple cerebral arteries. Modern Rheumatology Case Reports, 2018, 2, 214-220.	0.3	2

#	Article	IF	Citations
55	Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis. PLoS ONE, 2018, 13, e0206943.	1.1	15
56	Anti-EJ, anti-MDA5 double-positive chronic clinically amyopathic dermatomyositis: a case report. Rheumatology Advances in Practice, 2018, 2, rky022.	0.3	7
57	Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Research and Therapy, 2018, 20, 165.	1.6	33
58	Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Scientific Reports, 2018, 8, 10262.	1.6	54
59	Laminin 511 is a target antigen in autoimmune pancreatitis. Science Translational Medicine, 2018, 10, .	5.8	151
60	Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study. Rheumatology International, 2018, 38, 1679-1689.	1.5	12
61	5. Recent Progress of Diagnosis and Treatment in Connective Tissue Diseases. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1677-1687.	0.0	0
62	Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis. Modern Rheumatology, 2017, 27, 155-161.	0.9	21
63	Juvenile polymyositis associated with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody in a 13-year-old girl. Modern Rheumatology, 2017, 27, 541-544.	0.9	8
64	Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. Journal of Autoimmunity, 2017, 77, 116-122.	3.0	18
65	Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive. International Journal of Rheumatic Diseases, 2017, 20, 731-736.	0.9	3
66	Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases. Respiratory Investigation, 2017, 55, 130-137.	0.9	37
67	How to diagnose IgG4-related disease. Annals of the Rheumatic Diseases, 2017, 76, e46-e46.	0.5	33
68	Current approach to the diagnosis of IgG4-related disease – Combination of comprehensive diagnostic and organ-specific criteria. Modern Rheumatology, 2017, 27, 381-391.	0.9	175
69	The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respiratory Medicine, 2017, 127, 57-64.	1.3	37
70	Anti-carbamylated Protein Antibodies Are Detectable in Various Connective Tissue Diseases. Journal of Rheumatology, 2017, 44, 1384-1388.	1.0	16
71	Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Modern Rheumatology, 2017, 27, 755-765.	0.9	28
72	Genetic landscape of interactive effects of <i>HLA-DRB1 </i> li>alleles on susceptibility to ACPA(+) rheumatoid arthritis and ACPA levels in Japanese population. Journal of Medical Genetics, 2017, 54, 853-858.	1.5	3

#	Article	IF	CITATIONS
73	Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. Contemporary Clinical Trials Communications, 2017, 8, 49-54.	0.5	4
74	Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. Journal of Rheumatology, 2017, 44, 1394-1401.	1.0	37
75	Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. Respiratory Investigation, 2017, 55, 24-32	0.9	24
76	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Modern Rheumatology, 2017, 27, 217-226.	0.9	26
77	A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. Arthritis Research and Therapy, 2017, 19, 197.	1.6	29
78	Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS ONE, 2016, 11, e0154285.	1.1	102
79	Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort. PLoS ONE, 2016, 11, e0162896.	1.1	11
80	Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis. PLoS ONE, 2016, 11, e0167141.	1.1	24
81	Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. Journal of Rheumatology, 2016, 43, 1974-1983.	1.0	23
82	Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. Journal of Dermatological Science, 2016, 84, 272-281.	1.0	69
83	Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis. American Journal of Human Genetics, 2016, 99, 366-374.	2.6	68
84	Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respiratory Medicine, 2016, 121, 91-99.	1.3	121
85	GM-CSF as a therapeutic target in autoimmune diseases. Inflammation and Regeneration, 2016, 36, 8.	1.5	44
86	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). Rheumatology and Therapy, 2016, 3, 129-141.	1.1	3
87	The association between serious infection and disease outcome in patients with rheumatoid arthritis. Clinical Rheumatology, 2016, 35, 213-218.	1.0	10
88	International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Autoimmunity Highlights, 2016, 7, 1.	3.9	116
89	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Modern Rheumatology, 2016, 26, 80-86.	0.9	40
90	Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 3113-3123.	2.9	25

#	Article	IF	Citations
91	Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015. Frontiers in Immunology, 2015, 6, 412.	2.2	270
92	Prognostic Significance of Anti-Aminoacyl-tRNA Synthetase Antibodies in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease: A Retrospective Case Control Study. PLoS ONE, 2015, 10, e0120313.	1.1	74
93	Periodontitis and Porphyromonas gingivalis in Preclinical Stage of Arthritis Patients. PLoS ONE, 2015, 10, e0122121.	1.1	48
94	Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Research and Therapy, 2015, 17, 57.	1.6	48
95	Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon. Rheumatology, 2015, 54, 349-358.	0.9	14
96	Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. Arthritis Research and Therapy, 2015, 17, 104.	1.6	23
97	Screening for IgG4-type anti-nuclear antibodies in IgG4-related disease. BMC Musculoskeletal Disorders, 2015, 16, 129.	0.8	39
98	Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. Clinical Rheumatology, 2015, 34, 949-956.	1.0	21
99	Personal Authentication Analysis Using Finger-Vein Patterns in Patients with Connective Tissue Diseases—Possible Association with Vascular Disease and Seasonal Change PLoS ONE, 2015, 10, e0144952.	1.1	3
100	The Multicenter Study of a New Assay for Simultaneous Detection of Multiple Anti-Aminoacyl-tRNA Synthetases in Myositis and Interstitial Pneumonia. PLoS ONE, 2014, 9, e85062.	1.1	104
101	Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis. PLoS ONE, 2014, 9, e98202.	1.1	39
102	Brief Report: Autoantibodies to DNA Mismatch Repair Enzymes in Polymyositis/Dermatomyositis and Other Autoimmune Diseases: A Possible Marker of Favorable Prognosis. Arthritis and Rheumatology, 2014, 66, 3457-3462.	2.9	18
103	Human T cells expressing BEND3 on their surface represent a novel subpopulation that preferentially produces $La\in G$ and $La\in G$ . Immunity, Inflammation and Disease, 2014, 2, 35-43.	1.3	2
104	Deficient Leptin Signaling Ameliorates Systemic Lupus Erythematosus Lesions in MRL/Mp- <i>Faslpr</i> Mice. Journal of Immunology, 2014, 192, 979-984.	0.4	45
105	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014, 506, 376-381.	13.7	1,974
106	Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science, 2014, 346, 363-368.	6.0	86
107	GM-CSF but Not IL-17 Is Critical for the Development of Severe Interstitial Lung Disease in SKG Mice. Journal of Immunology, 2014, 193, 849-859.	0.4	53
108	Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Modern Rheumatology, 2013, 23, 430-439.	0.9	56

#	Article	IF	CITATIONS
109	The prognostic value of HRCT in myositis-associated interstitial lung disease. Respiratory Medicine, 2013, 107, 745-752.	1.3	95
110	Serum IgG levels demonstrate seasonal change in connective tissue diseases: a large-scale, 4-year analysis in Japanese. Modern Rheumatology, 2012, 22, 426-430.	0.9	4
111	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatology, 2012, 22, 21-30.	0.9	1,294
112	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Modern Rheumatology, 2012, 22, 1-14.	0.9	662
113	NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer RNA. Modern Rheumatology, 2012, 22, 685-694.	0.9	2
114	Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nature Genetics, 2012, 44, 511-516.	9.4	285
115	Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Research and Therapy, 2012, 14, R86.	1.6	58
116	ACPA-Negative RA Consists of Two Genetically Distinct Subsets Based on RF Positivity in Japanese. PLoS ONE, 2012, 7, e40067.	1.1	33
117	Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment. Current Rheumatology Reports, 2012, 14, 264-274.	2.1	139
118	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Modern Rheumatology, 2012, 22, 1-14.	0.9	453
119	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatology, 2012, 22, 21-30.	0.9	947
120	A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects. Annals of the Rheumatic Diseases, 2011, 70, 2134-2139.	0.5	42
121	Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respiratory Medicine, 2011, 105, 1238-1247.	1.3	100
122	HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respiratory Medicine, 2011, 105, 1380-1387.	1.3	118
123	Myelin Basic Protein as a Novel Genetic Risk Factor in Rheumatoid Arthritis—A Genome-Wide Study Combined with Immunological Analyses. PLoS ONE, 2011, 6, e20457.	1.1	29
124	The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Human Molecular Genetics, 2011, 20, 2680-2685.	1.4	90
125	Myositis autoantibodies in Korean patients with inflammatory myositis: Anti- $140$ -kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskeletal Disorders, 2010, $11$ , $223$ .	0.8	69
126	A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nature Genetics, 2010, 42, 515-519.	9.4	241

#	Article	IF	CITATIONS
127	Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. International Journal of Clinical Rheumatology, 2010, 5, 523-536.	0.3	18
128	Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology, 2010, 49, 2298-2304.	0.9	61
129	The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology, 2010, 49, 433-440.	0.9	284
130	Anti-MDA5 and anti-TIF1- $\hat{I}^3$ antibodies have clinical significance for patients with dermatomyositis. Rheumatology, 2010, 49, 1726-1733.	0.9	237
131	Two cases of late-onset drug-induced lupus erythematosus caused by ticlopidine in elderly men. Modern Rheumatology, 2010, 20, 405-409.	0.9	20
132	Vaccination with autoreactive CD4+Th1 clones in lupus-prone MRL/Mp-Faslpr/lpr mice. Journal of Autoimmunity, 2009, 33, 125-134.	3.0	12
133	Aseptic meningitis in mixed connective tissue disease: cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Modern Rheumatology, 2008, 18, 184-188.	0.9	20
134	Online First publication of <i>Modern Rheumatology</i> Modern Rheumatology, 2008, 18, 1-1.	0.9	2
135	Online First publication of Modern Rheumatology. Modern Rheumatology, 2008, 18, 1-1.	0.9	1
136	Severe subcutaneous generalized edema in a patient with dermatomyositis. Modern Rheumatology, 2007, 17, 171-173.	0.9	16
137	Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Current Opinion in Rheumatology, 2007, 19, 523-529.	2.0	143
138	Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Modern Rheumatology, 2007, 17, 167-170.	0.9	11
139	Clinical and immunogenetic features of patients with autoantibodies to asparaginyl–transfer RNA synthetase. Arthritis and Rheumatism, 2007, 56, 1295-1303.	6.7	101
140	Autoantibodies in Rheumatoid Arthritis. , 2006, , 277-290.		0
141	Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity, 2006, 39, 233-241.	1.2	174
142	Modern Rheumatology indexed in MEDLINE. Modern Rheumatology, 2006, 16, 123-123.	0.9	0
143	Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Modern Rheumatology, 2005, 15, 323-328.	0.9	43
144	Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis and Rheumatism, 2005, 52, 1571-1576.	6.7	627

#	Article	lF	CITATIONS
145	Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy. Journal of Rheumatology, 2004, 31, 1768-74.	1.0	44
146	Characterization of anticytoplasmic antibodies in patients with systemic autoimmune diseases. Modern Rheumatology, 2003, 13, 333-338.	0.9	0
147	Autoantibodies in Connective Tissue Diseases. Clinical Significance and Analysis of Target Autoantigens Internal Medicine, 1999, 38, 523-532.	0.3	25
148	Structures targeted by the immune system in myositis. Current Opinion in Rheumatology, 1996, 8, 521-527.	2.0	26
149	Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis and Rheumatism, 1996, 39, 1507-1518.	6.7	161
150	Clinical Significance of Antibodies to Native or Denatured 60-kd or 52-kd Ro/SS-A Proteins in Sjögren's Syndrome. Arthritis and Rheumatism, 1994, 37, 88-92.	6.7	31
151	Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in japanese patients with inflammatory muscle disease. Arthritis and Rheumatism, 1992, 35, 449-456.	6.7	127
152	Autoantigenic epitopes of the b polypeptide of SM small nuclear RNP particles. Arthritis and Rheumatism, 1992, 35, 960-966.	6.7	15
153	Detection of antibodies to small nuclear ribonucleoproteins and small cytoplasmic ribonucleoproteins using unlabeled cell extracts. Arthritis and Rheumatism, 1985, 28, 1356-1361.	6.7	118
154	Large cystic lesions of the upper lobes of the lungs in two patients with crest syndrome. Arthritis and Rheumatism, 1984, 27, 935-938.	6.7	3
155	The Precipitating Antibody to an Acidic Nuclear Protein Antigen, the Jo-1, in Connective Tissue Diseases. Arthritis and Rheumatism, 1983, 26, 604-611.	6.7	225